Suppression of cytotoxic T cell induction in vivo by prodigiosin 25-C

• Published in: Transplantation Vol. 47; no. 6; p. 1013
• Main Authors: Nakamura, A, Magae, J, Tsuji, R F, Yamasaki, M, Nagai, K
• Format: Journal Article
• Language: English
• Published: United States 01.06.1989
• Subjects: Animals; Antilymphocyte Serum - biosynthesis; Cells, Cultured; Cyclosporins - pharmacology; Cytotoxicity, Immunologic - drug effects; Immunosuppressive Agents - administration & dosage; Immunosuppressive Agents - pharmacology; Lymphocyte Activation - drug effects; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Prodigiosin - administration & dosage; Prodigiosin - pharmacology; Spleen; T-Lymphocytes, Cytotoxic - drug effects
• ISSN: 0041-1337
• DOI: 10.1097/00007890-198906000-00019

Prodigiosin 25-C (PrG25-C) was discovered as an immunosuppressant in the course of our screening for immunomodulating substances. In this system, PrG25-C inhibited T lymphocytes proliferation and was less suppressive against B lymphocytes. PrG25-C was also a powerful inhibitor of cytotoxic T cell induction by mixed lymphocyte reaction and completely suppressed induction of H-2 specific cytotoxic cells at 12.7 nM. PrG25-C also inhibited in vivo induction of H-2 restricted cytotoxic T lymphocytes at a dose of 0.5 mg/kg but had little myelotoxicity because numbers of blood leukocytes and splenocytes of PrG25-C-treated mice were comparable to those of nonsensitized mice. No inhibitory effects of PrG25-C were observed on the production of anti-SRBC antibody. These results indicate that PrG25-C is a T-lymphocyte-specific immunosuppressant.